HK1138272A1 - Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity - Google Patents

Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity

Info

Publication number
HK1138272A1
HK1138272A1 HK10104230.0A HK10104230A HK1138272A1 HK 1138272 A1 HK1138272 A1 HK 1138272A1 HK 10104230 A HK10104230 A HK 10104230A HK 1138272 A1 HK1138272 A1 HK 1138272A1
Authority
HK
Hong Kong
Prior art keywords
dpp
obesity
diabetes
treating
preventing
Prior art date
Application number
HK10104230.0A
Other languages
English (en)
Inventor
Heung Jae Kim
Woo Young Kwak
Chang Yell Shin
Hadong Kim
Jong Pil Min
Kyung Jin Park
Jae Young Lee
Song-Hyen Choi
Tae Hyun Yoon
Hae-Sun Kim
Ji Myun Jang
Mi-Kyung Kim
Moon-Ho Son
Soon Hoe Kim
Moohi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of HK1138272A1 publication Critical patent/HK1138272A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10104230.0A 2007-04-19 2010-04-29 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity HK1138272A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070038462 2007-04-19
PCT/KR2008/002203 WO2008130151A1 (en) 2007-04-19 2008-04-18 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity

Publications (1)

Publication Number Publication Date
HK1138272A1 true HK1138272A1 (en) 2010-08-20

Family

ID=39875638

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10104230.0A HK1138272A1 (en) 2007-04-19 2010-04-29 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
HK12112891.1A HK1172613A1 (zh) 2007-04-19 2012-12-13 包含β-氨基的 抑制劑及其製備方法以及用於預防和治療糖尿病或肥胖症的含有所述抑制劑的藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12112891.1A HK1172613A1 (zh) 2007-04-19 2012-12-13 包含β-氨基的 抑制劑及其製備方法以及用於預防和治療糖尿病或肥胖症的含有所述抑制劑的藥物組合物

Country Status (16)

Country Link
US (1) US8030315B2 (zh)
EP (1) EP2142519B1 (zh)
JP (1) JP5148686B2 (zh)
KR (1) KR101007497B1 (zh)
CN (2) CN101663282B (zh)
AU (1) AU2008241692B2 (zh)
BR (1) BRPI0810246B1 (zh)
CA (1) CA2683696C (zh)
ES (1) ES2526338T3 (zh)
HK (2) HK1138272A1 (zh)
IL (1) IL201524A (zh)
MX (1) MX2009011276A (zh)
NZ (1) NZ580701A (zh)
PT (1) PT2142519E (zh)
RU (1) RU2419615C1 (zh)
WO (1) WO2008130151A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CA2756915C (en) * 2009-03-30 2015-06-02 Dong-A Pharmaceutical Co., Ltd. Improved method for manufacturing dipeptidyl peptidase-iv inhibitor and intermediate
CN103922971B (zh) 2009-03-30 2016-05-11 东亚St株式会社 用于制备二肽基肽酶-iv抑制剂的中间体的改进方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
SG183817A1 (en) * 2010-03-24 2012-10-30 Dong A Pharm Co Ltd Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
CN102321014A (zh) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 新型双苯基吡啶类衍生物
WO2012166420A1 (en) * 2011-05-27 2012-12-06 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
ES2884815T3 (es) 2013-06-26 2021-12-13 Dong A St Co Ltd Composición para prevenir o tratar enfermedades renales, que comprende un inhibidor de DPP-IV
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN107382757A (zh) * 2017-08-11 2017-11-24 苏州信恩医药科技有限公司 不对称烯丙基取代反应在依格列汀中间体合成中的应用
CN107417554A (zh) * 2017-08-15 2017-12-01 苏州信恩医药科技有限公司 一种依格列汀中间体的合成方法
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002088070A (ja) * 2000-09-18 2002-03-27 Mitsubishi Rayon Co Ltd 新規ピペラジノン誘導体およびその製造方法
AU2003275404A1 (en) * 2002-10-07 2004-05-04 Merck & Co., Inc. Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2005011581A2 (en) 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1541143A1 (en) * 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
JP4704914B2 (ja) * 2003-12-11 2011-06-22 田辺三菱製薬株式会社 α−アミノ酸誘導体及びその医薬用途
EP1593671A1 (en) * 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
GB0413389D0 (en) 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
US20090124601A1 (en) 2005-03-29 2009-05-14 Song Zhiguo J Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体

Also Published As

Publication number Publication date
EP2142519A4 (en) 2011-07-13
CA2683696A1 (en) 2008-10-30
NZ580701A (en) 2011-07-29
PT2142519E (pt) 2014-12-11
BRPI0810246B1 (pt) 2021-11-30
MX2009011276A (es) 2010-01-15
RU2419615C1 (ru) 2011-05-27
AU2008241692B2 (en) 2011-02-10
KR101007497B1 (ko) 2011-01-12
US20100120790A1 (en) 2010-05-13
EP2142519A1 (en) 2010-01-13
CN101663282A (zh) 2010-03-03
ES2526338T3 (es) 2015-01-09
IL201524A0 (en) 2010-05-31
BRPI0810246A2 (pt) 2015-08-18
US8030315B2 (en) 2011-10-04
EP2142519B1 (en) 2014-09-24
HK1172613A1 (zh) 2013-04-26
WO2008130151A1 (en) 2008-10-30
AU2008241692A1 (en) 2008-10-30
JP2011500508A (ja) 2011-01-06
KR20080094604A (ko) 2008-10-23
CN102516184B (zh) 2015-03-25
IL201524A (en) 2014-09-30
JP5148686B2 (ja) 2013-02-20
CA2683696C (en) 2012-05-22
CN101663282B (zh) 2012-02-15
CN102516184A (zh) 2012-06-27

Similar Documents

Publication Publication Date Title
HK1138272A1 (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
ZA200711040B (en) Method and composition for transdermal drug delivery
IL185761A0 (en) Pharmaceutical compositions for treating diabetes
EP2048153A4 (en) SUBSTITUTED SPIROCETAL DERIVATIVE AND USE THEREOF AS A MEDICAMENT IN THE TREATMENT OF DIABETES
EP2080777A4 (en) CURABLE ORGANIC POLYMER, PROCESS FOR PRODUCING THE SAME, AND CURABLE COMPOSITION CONTAINING THE POLYMER
EP2240628A4 (en) RESIN-COATED STEEL SHEET, RESIN COMPOSITION THEREFOR, AND STEEL SHEET TREATMENT COMPOSITION
EP2199295A4 (en) 7-membered ring compounds and their pharmaceutical use for the prevention and treatment of diabetic and metabolic syndrome
HK1135338A1 (zh) 治療憂鬱症的藥物組合物及其製法
EP1906934A4 (en) DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
EP2172207A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES AND METHOD FOR THE PRODUCTION THEREOF
EP1896038A4 (en) METHOD AND COMPOSITION FOR THE TRANSDERMAL DISTRIBUTION OF MEDICINAL PRODUCTS
EP2030612A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING COMBUSTIONS (VARIATIONS) AND METHOD FOR THE PRODUCTION THEREOF (VARIANTS)
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
EP2127665A4 (en) MEDICAL PREPARATION BASED ON EXENATIDE AND DALARGINE FOR THE TREATMENT OF PANCREATIC DIABETES
EP1889618A4 (en) COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
EP2125700A4 (en) CALCIUM FUMARATE AND L-CARNITINE, PROCESS FOR THE PREPARATION THEREOF, AND APPLICATIONS THEREOF
ZA200710312B (en) An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating B Cell neoplasm
EP1781322A4 (en) METHOD OF TREATING DIABETES
IL185555A0 (en) Method and composition for treating diabetes
IL203064B (en) A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound
GB2435262B (en) Method, composition and articles
EP2163244A4 (en) MEDIUM, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING THE DEPENDENCE OF ETHYL ALCOHOL OR NARCOTICS
HK1097733A1 (en) A pharmaceutical compositin for treating diabetes and process thereof